tbuckley/cabot-search huggingface dataset:
Morbidity prior and after a diagnosis of sleep disordered breathing. A controlled national study
Authors: Poul Jennum, Jakob Kjellberg
Journal: European Respiratory Journal (2011)

Background: Sleep disordered breathing (SDB) cause's significant burden. Most studies have focused on cardiovascular diseases (CVD) after a diagnose of sleep apnea (SA) or obesity hypoventilation syndrome (OHS) but the overall morbidity prior to a SDB diagnose is incompletely evaluated.

Methods: Using data from the Danish National Patient Registry (1998-2006), we identified all national patients with a diagnosis of SA (19438), or OHS (755). For every patient, we randomly selected 4 age-, sex- and socioeconomic-matched citizens from the Danish Civil Registration System Statistics. We further extracted information from the Danish Ministry of Health, Danish Medicines Agency, and National Health Security

Results: Pts with SA and OHS presented increased morbidity (p<0.01) up to more than eight years prior to a SDB diagnose of SA the most common contacts were diseases of the endocrine, nutritional and metabolic diseases ((Odds Ratio (OR) SA/OHS 4.5/4.8), nervous system: OR 4.4/5.5), respiratory system (OR: 2.9/4.0)), skin and subcutaneous tissue (OR 2.5/1-3), infections (OR 1.8/3.0), CVD (OR 1.7/1.3), genito-urinary system (OR 1.3), ear-nose and throat (OR 1.3), psychiatric diseases (OR 1.1/1.4). After a SDB diagnose, patients also presented significant morbidities and mortality. CPAP treatment reduced mortality (6.6% versus 5.5 in SA pts, 4.0% in control subjects.

Conclusion: Patients with SDB shows significant morbidities several years prior to a diagnose of SA or OHS. As early detection of SA/OHS is important for improving prognosis, SDB should be considered in patient's with endocrine, nutritional, metabolic, neurological, pulmonary and CVD disorders.
Effect of setting of drug holidays on the efficacy of weekly higher shorter plus lower continuous (metronomic) five-fluorouracil (5-FU) concentration regimen in colorectal cancer
Authors: R. Yoshikawa, T. Hashimoto-Tamaoki, M. Gega, T. Yagyu, M. Noda, H. Yanagi
Journal: Journal of Clinical Oncology (2008)

13542 Background: Since the advent of various novel (molecular target) agents, it has been inevitable to reassure the dose regimen of 5-FU, a key drug in CRC. Recently, we have achieved good clinical benefits and cost-effectiveness in the treatment of CRC using ‘Pharmacokinetic Modulating Chemotherapy (PMC)’, which was designed as a hybrid of lower continuous (metronomic) and higher shorter plasma 5-FU concentration (Cancer 89: 1228, 2000, Cancer Res 61:1029, 2001, Proc ASCO 22: 1175, 2003). To establish a safer and more efficacious dose and scheduling of 5-FU administration from the perspective of cell cycle regulation, we investigated their anti-tumor efficiency by dose-enhancement and drug holidays, and the adverse events. Methods: First, weekly PMC regimens with or without dose-intensification and drug holidays were designed according to the mathematical model, and, then, experimented on the cell growth in vitro. Secondly, we assessed the clinical effects of the PMC regimens between “Tsunami 7” without drug holidays and “Tsunami 5” with a 2-day break (d 5–6) before a 1-day intensification (d 7), in Dukes’ B or C CRC patients (n=179), by the end-points of adverse events and 5-yr disease-free survival (DFS). Results: Adding 24-hr pharmacokinetic modulation by higher-dose intensification to the existing lower continuous (metronomic) formula succeeded in abrogation of the cell cycle block, leading to a nip in the steady tumor growth in vitro. Furthermore, setting of drug holidays seemed to change the cell cycle in favor of maximization of the targeted fraction. The clinical outcome of “Tsunami 5” regimen showed a tendency of less adverse events and improved 5-yr DFS than that of “Tsunami 7” (85% vs 75%, P=0.113). Conclusions: These results suggest that weekly 5-FU administration with a 2-day break before a 1-day intensification can be acceptable as an outpatient clinic first- line option because of reduced adverse events and maintained efficacy. Availability of efficacious chemotherapy reproduced by only oral agents (e.g. fluoropyrimidine, and leucovorin) mimicking the pharmacokinetics in this cell-cycle-oriented dose-dense “Tsunami” regimen would be beneficial for many cancer patients. No significant financial relationships to disclose.
Comparison of intravesical interleukin-12 gene therapy and intravesical BCG therapy for murine orthotopic bladder cancer model
Authors: Horinaga Minoru, Kelley Harsch, Ryuichi Fukuyama, Warren Heston, William Larchian
Journal: Cancer Research (2006)

4020   Introduction: Intravesical immunotherapy with bacillus Calmette-Guerin (BCG) is currently the most successful adjuvant agent for treating superficial bladder cancer. Intravesical BCG treatment was effective in wild type orthotopic bladder cancer model, while BCG was completely ineffective in IFNγ knock out and interleukin (IL-12) knock out orthotopic bladder cancer models. This study was designed to evaluate the antitumor effect of intravesical cationic liposome treatment of interleukin-12 (IL-12) in an orthotopic murine bladder cancer model and to compare the protective immunological memory against tumors between intravesical IL-12 gene therapy and intravesical BCG therapy. Methods. Superficial murine bladder cancer was established by simple instillation of 5 × 10 5  MBT-2 cells into the lumen of the bladder of female C3H/HeJ mouse through a urethral catheter. To assess the antitumor effect of IL-12, intravesical IL-12 therapy was evaluated at various doses: 0μg(control), 3μg, 5μg and 10μg (n=8). To assess the antitumor effect of BCG, intravesical BCG2 therapy was evaluated at various doses: 0μg(control), 100μg, and 400μg (n=10) Intravesical treatments were performed at 3day intervals and repeated 6 times starting from day 5 after tumor implantation. To compare the long- term tumor specific immunity between IL-12(5μg; n=18) and BCG (400μg; n=20), intravesical re-challengement of MBT-2 cells were performed for surviving mice and new control mice(n=10) at the day 60. These re-challenge survival mice as well as new control did not receive any further treatment. On the day120 all surviving mice were sacrificed and necropsied. Results. In the IL-12 groups at doses of 0μg, 3μg, 5μg and 10μg, 0, 2, 3 and 3 mice survived, respectively. Five and 10μg of IL-12 group demonstrated significantly longer survival than that of control group. In the BCG groups at doses of 0μg, 100μg, and 400μg, 0, 1 and 3 mice survived, respectively. All mice cured by IL-12 treatment successfully rejected the re-challenged MBT-2 cells, while mice cured by BCG and new control mice succumbed to the re-challenged bladder tumors. Conclusion. Intravesical IL-12 gene therapy which induced long-lasting tumor-specific immunological memory demonstrated the survival advantage in an ortrhotopic bladder cancer model. This finding of intravesical IL-12 gene therapy might be potentially advantages compared to intravesical BCG therapy.
Abstract 3544: Tumor suppressor function of loc285194 in breast cancer
Authors: YAYUN CHI, Sheng Huang, Jiong Wu
Journal: Cancer Research (2014)

Abstract Accumulating studies have focused on the oncogenic and tumor suppressive roles of the newly identified lncRNAs. LOC285194 was found to be associated with poor survival of osteosarcoma patients and colorectal cancer patients. Also loc285194 is reported to be a direct transcription target of p53 and could suppress cell growth. However, its role in breast cancer (BC) remains unknown. The aim of this study was to examine the expression pattern of loc285194 in BC and to evaluate its biological role and clinical significance in prediction of prognosis. In this study, we examined expression of loc285194 in 20 pairs of BC cancer tissues and adjacent noncancerous tissues (ANCT), also in 151 BC tissues, 14 BC cell lines and one normal breast cell line. It showed that loc285194 expression was lower both in BC samples and in BC cell lines compared with corresponding normal control. Loc285194 expression was correlated with menopausal status. Postmenopausal patients had a lower loc285194 expression level comparing with premenopausal patients (p=0.040). Moreover, low loc285194 expression was correlated with a relatively poor survival status (p=0.023) and a poor tumor differentiation (p=0.035). The Kaplan-Meier survival curves indicated that the overall survival (OS) was significantly poor in BC patients who showed low loc285194 expression. Furthermore, expression of loc285194 is significantly associated with worse prognosis independent of prognostic markers in estrogen receptor (ER) negative tumor samples (p = 0.05). Our studies indicate that loc285194 may represent a new marker of prognosis and it is a potential therapeutic target for breast cancer especially for ER negative breast cancer. Citation Format: YAYUN CHI, Sheng Huang, Jiong Wu. Tumor suppressor function of loc285194 in breast cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3544. doi:10.1158/1538-7445.AM2014-3544
Resveratrol increases the bone marrow hematopoietic stem and progenitor cell capacity
Authors: Pauline Rimmelé, Sébastien Lofek‐Czubek, Saghi Ghaffari
Journal: American Journal of Hematology (2014)

Resveratrol is a plant-derived polyphenol that has shown protective effects against many disorders including, several types of cancers and other age-associated diseases as well as blood disorders in cultured cells and/or animal models. However, whether resveratrol has any impact specifically on normal blood stem cells remains unknown. Here, we show that a 3-week treatment of resveratrol increases the frequency and total numbers of normal bone marrow hematopoietic stem cells (HSC) without any impact on their competitive repopulation capacity. In addition, we show that resveratrol enhances the bone marrow multipotent progenitor capacity in vivo. These results have therapeutic value for disorders of hematopoietic stem and progenitor cells (HSPC) as well as for bone marrow transplantation settings.
DYSCHONDROPLASIA WITH MULTIPLE HEMANGIOMATA (MAFFUCCI'S SYNDROME)
Authors: K MARBERG, F DALITH, H BANK
Journal: Annals of Internal Medicine (1958)

Case Reports1 November 1958DYSCHONDROPLASIA WITH MULTIPLE HEMANGIOMATA (MAFFUCCI'S SYNDROME)KURT MARBERG, M.D., FRITZ DALITH, M.D., HARRY BANK, M.B., Ch.B.KURT MARBERG, M.D.Search for more papers by this author, FRITZ DALITH, M.D.Search for more papers by this author, HARRY BANK, M.B., Ch.B.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-49-5-1216 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptA case of dyschondroplasia with multiple hemangiomata—Maffucci's syndrome—recently came under our observation. We believe this to be the thirty-fifth case to be described in the literature. The syndrome has been well summarized by Carleton et al.,1 Bean2 and Aimes.3 The rarity of the condition in itself justifies its being reported, and we feel that some features of this particular case, apparently less well known, may be of some importance to those interested in developmental abnormalities.CASE REPORTA 40 year old single female, born in Iraq, was admitted because of fever and a skin rash on the left breast for...Bibliography1. CarletonElkingtonGreenfieldRobb-Smith AJSJGAH: Maffucci's syndrome (dyschondroplasia with haemangeiomata), Quart. J. Med. 11: 203-228, 1942. Google Scholar2. Bean WB: Dyschondroplasia and hemangiomata (Maffucci's syndrome), Arch. Int. Med. 95: 767, 1955. CrossrefGoogle Scholar3. AimesFranchebois AP: Ostéochondrodysplasies et lésions associées. A propos d'un cas de syndrome de Maffucci, Semaine d. hôp. Paris 31: 363, 1955. MedlineGoogle Scholar4. ZellwegerUlinger HE: Ein Fall von halbseitiger Knochenchondromatose (Ollier) mit Naevus ichthyosiformis, Helvet. paediat. acta 3: 153, 1948. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Tel-Hashomer,*Received for publication October 15, 1957.From the Government Hospital, Tel-Hashomer, Israel.Requests for reprints should be addressed to Kurt Marberg, M.D., Head, 4th Internal Department, Government Hospital, Tel-Hashomer, Israel. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMaffucci's syndromeFehlbildungen der Haut und Hautveränderungen bei Fehlbildungssyndromen 1 November 1958Volume 49, Issue 5Page: 1216-1228KeywordsFeversInflammationRashes ePublished: 1 December 2008 Issue Published: 1 November 1958 PDF downloadLoading ...
Abstract 18081: Inverse Changes in Atrial Size During Obstructive Apnea
Authors: Gregg S Pressman, Beatriz Cepeda-Valery, Harish R Seetha Rammohan, Raul Moldovan, Marek Orban, Jay Horrow, Solomon P Samuel
Journal: Circulation (2014)

Introduction: Obstructive sleep apnea (OSA) is characterized by large swings in intrathoracic pressure. These pressure changes create an afterload burden on the left ventricle and presumably affect venous return to the right heart, and pooling of blood in the lungs. To better understand cardiac dynamics during OSA we used real time 2-D echocardiography to compare left (LA) and right atrial (RA) areas at baseline and during a series of gasping inspiratory efforts against an occluded airway. Hypothesis: Significant changes in atrial area will occur during inspiratory effort, with an inverse relationship between the two atria. Methods: Each of 14 healthy male subjects &lt;30 years, trained in the Mueller Maneuver (MM), made 5 to 6 maximal gasping efforts to simulate naturally occurring OSA. Concomitant echocardiographic loops were acquired using the apical 4 chamber view. Results: Average baseline (end-systolic) atrial area was 16.6 ± 0.837 cm2 (100 beats; mean ± pooled SD) for the LA and 16.3 ± 0.931 cm2 for the RA. During the MM average LA area was 16.7 ± 1.29 cm2 (252 beats) and average RA area was 15.4 ± 1.69 cm2. For left and right separately, variance in atrial area during the MM exceeded that at baseline (p&lt;0.0001, F-test). During the MM, LA variance increased to 2.38-fold that of baseline, RA variance to 3.30-fold. Further, there was an inverse relationship between LA and RA area during the MM (graph). Visual inspection of digitized loops revealed a sudden decrease in LA area with inspiratory effort. Conclusions: Performance of the MM as a series of gasping efforts (designed to mimic natural OSA) produced marked and mutually inverse variation in LA and RA area as compared with baseline. LA area decreased abruptly with onset of negative inspiratory pressure. Such changes, repeated hundreds of times per night, have the potential to alter atrial structure and function. These data may help explain the strong association between obstructive sleep apnea and atrial fibrillation.
Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981
Authors: G. Neckermann, A. Bavandi, J.G. Meingassner
Journal: British Journal of Dermatology (2000)

Magnesium deficiency in hairless rats results in a transient erythematous rash within several days, the pathogenetic mechanisms of which are not yet well defined. However, the extremely pruritic rash closely mimics the acute clinical features of atopic dermatitis. Owing to the similarity of clinical signs between hypomagnesaemic rats and patients with atopic dermatitis, this rodent skin condition holds promise as a model for the in vivo evaluation of new treatment modalities against pruritic inflammatory skin conditions. The efficacy of the new ascomycin macrolactam derivative SDZ ASM 981 was tested in hypomagnesaemic rats by systemic or topical administration using prophylactic or therapeutic treatment regimens. Oral treatment of diseased rats with SDZ ASM 981 (12.5 mg kg-1 daily) inhibited the erythematous pruritic rash within 1 day after the start of treatment. This was associated with a clear reduction in histaminaemia, leucocytosis, eosinophilia and serum nitric oxide levels. The same daily oral dose of SDZ ASM 981 administered before the onset of the rash proved to be an efficacious prophylactic treatment regimen to prevent signs. Topical treatment of the ears with 0.4% SDZ ASM 981 locally inhibited and prevented inflammatory changes in a therapeutic and prophylactic treatment regimen, respectively. The histo- and immunopathological skin changes, as well as the numbers of degranulated mast cells in the dermis, were reversed towards normal after oral and topical administration. The pharmacological activity of SDZ ASM 981 reported here corresponds well to its anti-inflammatory and antipruritic activity observed in atopic dermatitis patients, confirming the usefulness of this rat model in drug evaluations.
Chromosomal and Gene Amplification in Diffuse Large B-Cell Lymphoma
Authors: Pulivarthi H. Rao, Jane Houldsworth, Katerina Dyomina, Nasser Z. Parsa, Juan C. Cigudosa, Diane C. Louie, Leslie Popplewell, Kenneth Offit, Suresh C. Jhanwar, R.S.K. Chaganti
Journal: Blood (1998)
ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting
Authors: Eric R. Bates, Joseph D. Babb, Donald E. Casey, Christopher U. Cates, Gary R. Duckwiler, Ted E. Feldman, William A. Gray, Kenneth Ouriel, Eric D. Peterson, Kenneth Rosenfield, John H. Rundback, Robert D. Safian, Michael A. Sloan, Christopher J. White, Robert A. Harrington, Jonathan Abrams, Jeffrey L. Anderson, Eric R. Bates, Mark J. Eisenberg, Cindy L. Grines, Mark A. Hlatky, Robert C. Lichtenberg, Jonathan R. Lindner, Gerald M. Pohost, Richard S. Schofield, Samuel J. Shubrooks, James H. Stein, Cynthia M. Tracy, Robert A. Vogel, Deborah J. Wesley
Journal: Journal of the American College of Cardiology (2007)
763. Size-Dependent Packaging and Transgene Expression of Double-Stranded AAV Vectors
Authors: Zhong Wang, gregory szeto, Jian Zhang, Juan Li, Xiao Xiao
Journal: Molecular Therapy (2004)

Efforts to improve the potency of AAV mediated gene transfer should greatly benefit its application as a gene transfer vector, especially in human gene therapy applications, in which large amounts of viral particles are usually required to achieve the desirable therapeutic effects. A genome-modified strategy recently demonstrated by us and others dramatically accelerated and improved AAV mediated gene transfer, holding great promise. This strategy is characterized by rendering AAV vectors predominantly packaging a double-stranded (ds) DNA as genome via mutating one inverted terminal repeat (ITR). In current studies, we further attempted to define the optimal packaging capacity of dsAAV. Vectors of various length between the two ITRs arranging from 1871 base pairs (bp) to 6362 bp were characterized by Southern analysis. We found that the packaging of dsAAV vector is size dependent, with dsAAV vectors less than its packaging capacity (around 2440 bp-2487 bp) predominantly encapsulated full- length ds DNA as their genomes. However, the genomes of over-sized dsAAV vectors were also packaged, containing a smear of partially packaged DNA molecules. The DNA sizes spanned from corresponding single-stranded length to around 4.8 kilonucleotides, dominated by single-stranded DNA molecules and certain length of partial ds DNA molecules. The results suggest that AAV packaging machinery attempts to use sub-optimal excision sites to remove the excessive DNA in the absence of a wild type ITR and trs, prior to the completion of viral particle assembly. In vitro and in vivo infection studies showed that the over-sized, partial dsAAV vectors still exhibited higher transgene expressions in vitro and in vivo than the control single-stranded AAV vector, albeit lower than the fully dsAAV vectors. These findings should have important implications for elucidating the packaging process of AAV virions as well as on the usage of dsAAV as a gene delivery vector.
Nobel prize for medicine awarded for work on nitric oxide
Authors: Marcus Müllner
Journal: BMJ (1998)

Three American pharmacologists have won this year's Nobel prize for medicine for their work on nitric oxide as a signalling molecule in the cardiovascular system.

Robert Furchgott, Ferid Murad, and Louis Ignarro discovered how nitric oxide could be produced by endothelial cells, penetrate membranes, and regulate the function of another cell. Current understanding of the vascular pathophysiology …
Sexual Neurasthenia (Nervous Exhaustion), Its Hygiene, Causes, Symptoms and Treatment, with a chapter on diet for the nervous.
Authors: George Miller Beard, A. D. Rockwell
Journal: JAMA (1895)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PATHOLOGY OF THE FINGER NAIL IN PSORIASIS.
Authors: KLAUS LEWIN, SHARON DEWIT, RICHARD A. FERRINGTON
Journal: British Journal of Dermatology (1972)

Journal Article PATHOLOGY OF THE FINGER NAIL IN PSORIASIS: A CLINICOPATHOLOGICAL STUDY Get access KLAUS LEWIN, KLAUS LEWIN Department of Pathology and Dermatology, Stanford University School of Medicine, California 94305, U.S.A Search for other works by this author on: Oxford Academic Google Scholar SHARON DEWIT, SHARON DEWIT Department of Pathology and Dermatology, Stanford University School of Medicine, California 94305, U.S.A Search for other works by this author on: Oxford Academic Google Scholar RICHARD A. FERRINGTON RICHARD A. FERRINGTON Department of Pathology and Dermatology, Stanford University School of Medicine, California 94305, U.S.A Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 86, Issue 6, 1 June 1972, Pages 555–563, https://doi.org/10.1111/j.1365-2133.1972.tb05069.x Published: 01 June 1972 Article history Accepted: 25 January 1972 Published: 01 June 1972